General contact

Head Office
Novartis International AG
CH-4002 Basel
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)

Investors

Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland

+41 61 324 79 44

Media

Global Oncology Media Relations
Denise Brashear
Novartis Oncology Global Public Relations

+1 862 778 7336

Novartis Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

pane 4 content

This site is not intended for U.S. residents.

Novartis Oncology Alliances

At Novartis Oncology, we are passionate about providing a broad range of new remedies and practical solutions that change the way patients live with cancer. Open Partnerships allow us to gain insights and build knowledge, driving clinical development based on scientific and patient insights. As part of our commitment to patients and health care professionals, we have developed Alliance sites with patient support materials, educational materials, clinical trial information and more.

  • GIST Alliance™

    GIST Alliance™ is a unique support program designed to help health care professionals optimize treatment outcomes in gastrointestinal stromal tumor (GIST) patients. GISTs are currently the most common mesenchymal tumors of the gastrointestinal tract, with an estimated 3,300 to 6,000 new cases reported each year in the United States.1,2 Approximately 2,500 of these cases are metastatic at diagnosis.3

    GIST Alliance Website

    Visit the GIST Alliance™ site for gastrointestinal stromal tumors

  • Iron Health Alliance™

    The Iron Health Alliance™ is designed to increase awareness, provide support, and educate physicians and patients about iron toxicity. New research and diagnostic methods continue to drive clinical progress. These advancements translate into widespread patient benefits by enhancing education, improving access related to diagnostics, understanding adherence and encouraging higher standards of care.

    Iron Health Alliance Website

  • NET Alliance™

    Neuroendocrine tumors, also known as NETs, are an uncommon type of cancer that is sometimes referred to as carcinoid. The NET Alliance™ is designed to help patients and caregivers better understand NETs and connect with one another to advance the knowledge and management of neuroendocrine tumors.

    NET Alliance Website

    Visit the NET Alliance™ site for neuroendocrine tumors

References:

  1. Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol Mech Dis. 2008;3:557-586.
  2. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN task force report: management of patients with gastrointestinal stromal tumor (GIST)–update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007;5(suppl2):S1-29.
  3. Griffin JM, St Amand M, Demetri GD. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors. Clin J Oncol Nurs. 2005;9(2):161-169.